MDA7: A novel selective agonist for CB 2 receptors that prevents allodynia in rat neuropathic pain models

British Journal of Pharmacology

Volumn 155, Issue 7, 2008, Pages 1104-1116

  Naguib, M ^a   Diaz, P ^a   Xu, J J ^a   Astruc Diaz, F ^a   Craig, S ^a   Vivas Mejia, P ^a   Brown, D L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allodynia; Cancer; Cannabinoid; CB 2; Chemotherapy; Hyperalgesia; MDA7; Neuropathic pain

Indexed keywords

1 [(3 BENZYL 3 METHYL 2,3 DIHYDRO 1 BENZOFURAN 6 YL)CARBONYL]PIPERIDINE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; MDA 7; OPIATE ANTAGONIST; PACLITAXEL; RADIOLIGAND; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; EXPERIMENTAL MODEL; HUMAN; IN VITRO STUDY; LOCOMOTION; MALE; NERVE LIGATION; NEUROPATHIC PAIN; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIOASSAY; RAT; RECEPTOR AFFINITY; SPINAL NERVE;

ANALGESICS; ANIMALS; BENZOFURANS; CHO CELLS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIGATION; MOTOR ACTIVITY; NEURALGIA; PACLITAXEL; PAIN MEASUREMENT; PIPERIDINES; RADIOLIGAND ASSAY; RATS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SPECIES SPECIFICITY; SPINAL NERVES;

EID: 56749169196     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.340     Document Type: Article

References (71)

1. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S et al. (2007). Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68: 515-521.
2. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl 2): S1-S209.
3. Ashton JC, Class M (2007). The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr neuropharmacol 5: 73-80.
4. Authier N, Dupuis E, Kwasiborski A, Eschalier A, Coudore F (2002). Behavioural assessment of dimethylsulfoxide neurotoxicity in rats. Toxicol Lett 132: 117-121.
5. Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S et al. (2006). CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 23: 1530-1538.
6. Berman JS, Symonds C, Birch R (2004). Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 112: 299-306.
7. Bingham B, Jones PG, Uveges AJ, Kotnis S, Lu P, Smith VA et al. (2007). Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol 151: 1061-1070.
8. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL (1994). Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53: 55-63.
9. Chin CL, Tovcimak AE, Hradil VP, Seifert TR, Hollingsworth PR, Chandran P et al. (2008). Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. Br J Pharmacol 153: 367-379.
10. Conti S, Bertorelli R, Forlani A, Fredduzzi S, Nicolussi E, Reggiani A (2007). Role of GW842166X, a CB2 receptor agonist, in several rat models of neuropathic and inflammatory pain. In: 33 Congresso Nazionale della Societa Italiana di Farmacologia. Societa Italiana di Farmacologia: Cagliari, Sardinia, Italy, p 50.
11. Cox ML, Haller VL, Welch SP (2007). The antinociceptive effect of [Delta]9-tetrahydrocannabinol in the arthritic rat involves the CB2 cannabinoid receptor. Eur J Pharmacol 570: 50-56.
12. Davis MP (2007). What is new in neuropathic pain? Support Care Cancer 15: 363-372.
13. Devane WA, Dysarz III FA, Johnson MR, Melvin LS, Howlett AC (1988). Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34: 605-613.
14. Diaz P, Xu JJ, Astruc-Diaz F, Pan H-M, Brown DL, Naguib M (2008). Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective CB2 agonists for the treatment of neuropathic pain. J Med Chem 31 July 2008 [Epub ahead of print]. doi: http://dx.doi.org/10.1021/ jm8002203.
15. Dixon W (1965). The up-and-down method for small samples. J Am Stat Assoc 60: 967-978.
16. Edgar KJ, Falling SN (1990). An efficient and selective method for the preparation of iodophenols. J Org Chem 55: 5287-5291.
17. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 92: 3376-3380.
18. Gatley SJ, Gifford AN, Volkow ND, Lan R, Makriyannis A (1996). 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur J Pharmacol 307: 331-338.
19. Gerard CM, Mollereau C, Vassart G, Parmentier M (1991). Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 279 (Part 1): 129-134.
20. Giblin GMP, O'Shaughnessy CT, Naylor A, Mitchell WL, Eatherton AJ, Slingsby BP et al. (2007). Discovery of 2-[(2,4-Dichlorophenyl) amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl) -5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. J Med Chem 50: 2597-2600.
21. Gonsiorek W, Lunn CA, Fan X, Deno G, Kozlowski J, Hipkin RW (2007). Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB2) in rodents and primates. Br J Pharmacol 151: 1262-1271.
22. Govaerts SJ, Hermans E, Lambert DM (2004). Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. Eur J Pharm Sci 23: 233-243.
23. Guindon J, Hohmann AG (2008). Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153: 319-334.
24. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M et al. (1999). HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96: 14228-14233.
25. Herzberg U, Eliav E, Bennett GJ, Kopin IJ (1997). The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 221: 157-160.
26. Holdcroft A, Maze M, Dore C, Tebbs S, Thompson S (2006). A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 104: 1040-1046.
27. 35S]GTP gamma S binding in the mouse brain. Eur J Pharmacol 321: R1-R3.
28. Hucker HB, Miller JK, Hochberg A, Brobyn RD, Riordan FH, Calesnick B (1967). Studies on the absorption, excretion and metabolism of dimethylsulfoxide (DMSO) inman. J Pharmacol Exp Ther 155: 309-317.
29. Huffman JW (2005). CB2 receptor ligands. Mini Rev Med Chem 5: 641-649.
30. Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, Compton DR et al. (1996). Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 39: 3875-3877.
31. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP et al. (2003). Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100: 10529-10533.
32. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A et al. (2005). CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 102: 3093-3098.
33. Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW et al. (2006). CB2 cannabinoid receptor mediation of antinociception. Pain 122: 36-42.
34. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U (2003). Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 290: 1757-1762.
35. Khaliq W, Alam S, Puri N (2007). Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev 2: CD004846.
36. Kikuchi A, Ohashi K, Sugie Y, Sugimoto H, Omura H (2008). Pharmacological evaluation of a novel cannabinoid 2 (CB(2)) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. J Pharmacol Sci 106: 219-224.
37. Kim SH, Chung JM (1992). An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50: 355-363.
38. Kocsis JJ, Harkaway S, Snyder R (1975). Biological effects of the metabolites of dimethyl sulfoxide. Ann NY Acad Sci 243: 104-109.
39. LaBuda CJ, Koblish M, Little PJ (2005). Cannabinoid CB2 receptor agonist activity in the hindpaw incision: model of postoperative pain. Eur J Pharmacol 527: 172-174.
40. Malan Jr TP, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T et al. (2001). CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93: 239-245.
41. Manera C, Benetti V, Castelli MP, Cavallini T, Lazzarotti S, Pibiri F et al. (2006). Design, synthesis, and biological evaluation of new 1,8-Naphthyridin-4(1H)-on-3-carboxamide and Quinolin-4(1H)-on-3- carboxamide derivatives as CB2 selective agonists. J Med Chem 49: 5947-5957.
42. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
43. Mukherjee S, Adams M, Whiteaker K, Daza A, Kage K, Cassar S et al. (2004). Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. Eur J Pharmacol 505: 1-9.
44. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65.
45. 2 cannabinoid Ligand 1-(2′,4′-Dichlorophenyl)-6-methyl-N-piperidin-1-yl-1, 4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. J Med Chem 49: 7502-7512.
46. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D (2007). Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 133: 210-220.
47. Ohta H, Ishizaka T, Tatsuzuki M, Yoshinaga M, Iida I, Tomishima Y et al. (2007a). N-Alkylidenearylcarboxamides as new potent and selective CB2 cannabinoid receptor agonists with good oral bioavailability. Bioorg Med Chem Lett 17: 6299-6304.
48. Ohta H, Ishizaka T, Yoshinaga M, Morita A, Tomishima Y, Toda Yet al. (2007b). Sulfonamide derivatives as new potent and selective CB2 cannabinoid receptor agonists. Bioorg Med Chem Lett 17: 5133-5135.
49. Onaivi ES, Ishiguro H, Gong J-P, Patel S, Perchuk A, Meozzi PA et al. (2006). Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann NY Acad Sci 1074: 514-536.
50. Overton HA, Babbs AJ, Doel SM, Fyfe MCT, Gardner LS, Griffin G et al. (2006). Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metabol 3: 167-175.
51. Page D, Yang H, Brown W, Walpole C, Fleurent M, Fyfe M et al. (2007). New 1,2,3,4-tetrahydropyrrolo[3,4-b]indole derivatives as selective CB2 receptor agonists. Bioorg Med Chem Lett 17: 6183-6187.
52. Polomano RC, Mannes AJ, Clark US, Bennett GJ (2001). A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 94: 293-304.
53. Rahn EJ, Makriyannis A, Hohmann AG (2007). Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 152: 765-777.
54. Reggio PH (2003). Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors. Curr Pharm Des 9: 1607-1633.
55. Romero-Sandoval A, Eisenach JC (2007). Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision. Anesthesiology 106: 787-794.
56. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A et al. (1999). Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126: 665-672.
57. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092-1101.
58. Salo OMH, Raitio KH, Savinainen JR, Nevalainen T, Lahtela-Kakkonen M, Laitinen JT et al. (2005). Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. J Med Chem 48: 7166-7171.
59. Szlosek-Pinaud M, Diaz P, Martinez J, Lamaty F (2007). Efficient synthetic approach to heterocycles possessing the 3,3-disubstituted-2,3- dihydrobenzofuran skeleton via diverse palladium-catalyzed tandem reactions. Tetrahedron 63: 3340-3349.
60. Tallarida RJ, Murray RB (1987). Manual of Pharmacologic Calculations with Computer Programs 2nd edn, Springer-Verlag: New York.
61. Tassone DM, Boyce E, Guyer J, Nuzum D (2007). Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 29: 26-48.
62. Torrance N, Smith BH, Bennett MI, Lee AJ (2006). The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 7: 281-289.
63. Turk DC (2002). Clinical effectiveness and cost-effectiveness of treatments for patients with chronic pain. Clin J Pain 18: 355-365.
64. Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL et al. (2005). Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48: 658-672.
65. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K et al. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310: 329-332.
66. Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P (2005). Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. Neuroscience 132: 1093-1102.
67. Warms CA, Turner JA, Marshall HM, Cardenas DD (2002). Treatments for chronic pain associated with spinal cord injuries: many are tried, few are helpful. Clin J Pain 18: 154-163.
68. Whiteside GT, Lee GP, Valenzano KJ (2007). The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr Med Chem 14: 917-936.
69. Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A (2005). Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage 29: 358-367.
70. Wotherspoon G, Fox A, McIntyre P, Colley S, Bevan S, Winter J (2005). Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135: 235-245.
71. Yao BB, Hsieh GC, Frost JM, Fan Y, Garrison TR, Daza AVet al. (2008). In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol 153: 390-401.